Skip to main content

SABCS: Neoadjuvant Chemo Can Let Breast Cancer Patients Skip Nodal RT

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 7, 2023.

By Elana Gotkine HealthDay Reporter

THURSDAY, Dec. 7, 2023 -- Patients who present with breast cancer with axillary node involvement (cN+) who are found to be pathologically node-negative at surgery (ypN0) after neoadjuvant chemotherapy can avoid regional nodal irradiation (RNI), according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 5 to 9 in San Antonio.

Eleftherios (Terry) Mamounas, M.D., M.P.H., from the University of Central Florida in Orlando, and colleagues conducted a trial enrolling 1,641 patients to examine whether adjuvant RNI including the chest wall after mastectomy or addition of RNI to whole breast irradiation after breast-conserving surgery (BCS) improves the invasive breast cancer recurrence-free interval (IBC-RFI) in patients who present with cN+ who are ypN0 at surgery after neoadjuvant chemotherapy. Patients were randomly assigned to no RNI versus RNI after BCS. The primary event analysis included 1,556 patients.

The researchers found that at the time of the analysis, 109 IBC-RFI events were confirmed (59 with no RNI versus 50 with RNI). Between the groups, there was no statistically significant difference observed for IBC-RFI, with five-year point estimates of 91.8 and 92.7 percent for no RNI and RNI, respectively. No significant between-group differences were seen for secondary end points.

"Our findings suggest that downstaging cancer-positive regional lymph nodes with neoadjuvant chemotherapy can allow some patients to skip adjuvant RNI without adversely affecting oncologic outcomes," Mamounas said in a statement. "Follow-up of patients for long-term outcomes continues."

Mamounas disclosed ties to the biopharmaceutical industry.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Inavolisib + Palbociclib-Fulvestrant Improves Survival in Advanced Breast Cancer

THURSDAY, Oct. 31, 2024 -- Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus palbociclib-fulvestrant in patients with...

Multigene Signature Can Help Tailor Chemo for Operable Triple-Negative Breast Cancer

WEDNESDAY, Oct. 30, 2024 -- For patients with operative triple-negative breast cancer, a multigene signature can help tailor adjuvant chemotherapy, according to a study published...

Guideline-Concordant Care Less Likely With Non-Hispanic Black Race

TUESDAY, Oct. 29, 2024 -- For older patients with breast cancer, non-Hispanic Black race is associated with increased odds of not receiving guideline-concordant care (GCC) and...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.